LRP and senile plaques in Alzheimer's disease:: colocalization with apolipoprotein E and with activated astrocytes

被引:81
作者
Arélin, K
Kinoshita, A
Whelan, CM
Irizarry, MC
Rebeck, GW
Strickland, DK
Hyman, BT
机构
[1] Massachusetts Gen Hosp, Alzheimers Res Unit, Dept Neurol, Charlestown, MA 02129 USA
[2] Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA
来源
MOLECULAR BRAIN RESEARCH | 2002年 / 104卷 / 01期
关键词
Alzheimer; LRP; astrocyte; apoE; PDAPP mice;
D O I
10.1016/S0169-328X(02)00203-6
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The low density lipoprotein receptor-related protein (LRP) is a multifunctional receptor which is present on senile plaques in Alzheimer's disease (AD). It is suggested to play an important role in the balance between amyloid beta (Abeta) synthesis and clearance mechanisms. One of its ligands, apolipoprotein E (apoE), is also present on senile plaques and has been implicated as a risk factor for AD, potentially affecting the deposition, fibrillogenesis and clearance of Abeta. Using immunohistochemistry we show that LRP was present only on cored, apoE-containing senile plaques, in both PDAPP transgenic mice and human AD brains. We detected strong LRP staining in neurons and in reactive astrocytes, and immunostaining of membrane-bound LRP showed colocalization with line astrocytic processes surrounding senile plaques. LRP was not present in plaques in young transgenic mice or in plaques of APOE-knockout mice. As LRP ligands associated with Abeta deposits in AD brain may play an important role in inducing levels of LRP in both neurons and astrocytes, our findings support the idea that apoE might be involved in upregulation of LRP (present in fine astrocytic processes) and act as a local scaffolding protein for LRP and Abeta. The upregulation of LRP would allow increased clearance of LRP ligands as well as clearance of AP/ApoE complexes. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:38 / 46
页数:9
相关论文
共 52 条
  • [1] IMMUNOCHEMICAL IDENTIFICATION OF THE SERINE PROTEASE INHIBITOR ALPHA-1-ANTICHYMOTRYPSIN IN THE BRAIN AMYLOID DEPOSITS OF ALZHEIMERS-DISEASE
    ABRAHAM, CR
    SELKOE, DJ
    POTTER, H
    [J]. CELL, 1988, 52 (04) : 487 - 501
  • [2] Ard MD, 1996, J NEUROSCI RES, V43, P190, DOI 10.1002/(SICI)1097-4547(19960115)43:2<190::AID-JNR7>3.0.CO
  • [3] 2-B
  • [4] Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition
    Bales, KR
    Verina, T
    Dodel, RC
    Du, YS
    Altstiel, L
    Bender, M
    Hyslop, P
    Johnstone, EM
    Little, SP
    Cummins, DJ
    Piccardo, P
    Ghetti, B
    Paul, SM
    [J]. NATURE GENETICS, 1997, 17 (03) : 263 - 264
  • [5] INTERLEUKIN-6 AND ALPHA-2-MACROGLOBULIN INDICATE AN ACUTE-PHASE STATE IN ALZHEIMERS-DISEASE CORTICES
    BAUER, J
    STRAUSS, S
    SCHREITERGASSER, U
    GANTER, U
    SCHLEGEL, P
    WITT, I
    YOLK, B
    BERGER, M
    [J]. FEBS LETTERS, 1991, 285 (01) : 111 - 114
  • [6] Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures
    Beffert, U
    Aumont, N
    Dea, D
    Lussier-Cacan, S
    Davignon, J
    Poirier, J
    [J]. MOLECULAR BRAIN RESEARCH, 1999, 68 (1-2): : 181 - 185
  • [7] Modulation of the alpha(2) macroglobulin receptor low density lipoprotein receptor related protein by interferon-gamma in human astroglial cells
    Businaro, R
    Fabrizi, C
    Persichini, T
    Starace, G
    Ennas, MG
    Fumagalli, L
    Lauro, GM
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1997, 72 (01) : 75 - 81
  • [8] FIBRILLOGENESIS IN ALZHEIMERS-DISEASE OF AMYLOID-BETA PEPTIDES AND APOLIPOPROTEIN-E
    CASTANO, EM
    PRELLI, F
    WISNIEWSKI, T
    GOLABEK, A
    KUMAR, RA
    SOTO, C
    FRANGIONE, B
    [J]. BIOCHEMICAL JOURNAL, 1995, 306 : 599 - 604
  • [9] Chen KS, 1998, PROG BRAIN RES, V117, P327
  • [10] Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Aβ aggregation
    Cho, HS
    Hyman, BT
    Greenberg, SM
    Rebeck, GW
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (04) : 342 - 349